Article
Hematology
John H. Baird, Matthew J. Frank, Juliana Craig, Shabnum Patel, Jay Y. Spiegel, Bita Sahaf, Jean S. Oak, Sheren F. Younes, Michael G. Ozawa, Eric Yang, Yasodha Natkunam, John Tamaresis, Zachary Ehlinger, Warren D. Reynolds, Sally Arai, Laura Johnston, Robert Lowsky, Everett Meyer, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Surbhi Sidana, Wen-Kai Weng, Kara L. Davis, Sneha Ramakrishna, Liora Schultz, Chelsea Mullins, Allison Jacob, Ilan Kirsch, Steven A. Feldman, Crystal L. Mackall, David B. Miklos, Lori Muffly
Summary: Despite poor prognosis in LBCL patients following CAR19 therapy failure, treatment with CAR22 in three consecutive patients showed promising results with all patients achieving complete remission and experiencing tolerable side effects, suggesting potential efficacy of CAR22 therapy in this population.
Article
Biochemistry & Molecular Biology
Andreas Mackensen, Fabian Mueller, Dimitrios Mougiakakos, Sebastian Boeltz, Artur Wilhelm, Michael Aigner, Simon Voelkl, David Simon, Arnd Kleyer, Luis Munoz, Sascha Kretschmann, Soraya Kharboutli, Regina Gary, Hannah Reimann, Wolf Roesler, Stefan Uderhardt, Holger Bang, Martin Herrmann, Arif Buelent Ekici, Christian Buettner, Katharina Maria Habenicht, Thomas H. Winkler, Gerhard Kroenke, Georg Schett
Summary: A study of five patients with refractory systemic lupus erythematosus treated with anti-CD19 CAR T cell therapy showed remission of SLE disease in all patients after 3 months, and long-term drug-free remission was maintained during follow-up.
Article
Immunology
Changju Qu, Rui Zou, Peng Wang, Qian Zhu, Liqing Kang, Nana Ping, Fan Xia, Hailing Liu, Danqing Kong, Lei Yu, Depei Wu, Zhengming Jin
Summary: This study demonstrates that CD19/CD22 dual-targeted CAR-T therapy, under a decitabine-containing lymphodepletion regimen, may be a safe and potent effective approach for patients with relapsed/refractory DLBCL.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Yao Sun, Yongfeng Su, Yizhi Wang, Na Liu, Yuhang Li, Jianlin Chen, Zhuoqing Qiao, Jingwen Niu, Jiangwei Hu, Bin Zhang, Hongmei Ning, Liangding Hu
Summary: The study presented a case of a patient with B-ALL who experienced extramedullary relapse after allogeneic stem cell transplantation and underwent multiple CAR-T cell therapies, including different variants of CD19 CAR-T cells. The patient achieved therapeutic responses after some of the treatments, demonstrating the potential efficacy of CAR-T cell therapy in relapsed B-ALL patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Clara Bueno, Susana Barrera, Alex Bataller, Valentin Ortiz-Maldonado, Natalina Elliot, Sorcha O'Byrne, Guanlin Wang, Montse Rovira, Francisco Gutierrez-Aguera, Juan L. Trincado, Maria Gonzalez-Gonzalez, Mireia Morgades, Marc Sorigue, Paloma Barcena, Samanta Romina Zanetti, Montse Torrebadell, Nerea Vega-Garcia, Susana Rives, Mar Mallo, Francesc Sole, Adam J. Mead, Irene Roberts, Supat Thongjuea, Bethan Psaila, Manel Juan, Julio Delgado, Alvaro Urbano-Ispizua, Josep Maria Ribera, Alberto Orfao, Anindita Roy, Pablo Menendez
Summary: CD19-directed immunotherapies have greatly improved the treatment of B-cell acute lymphoblastic leukemia (B-ALL). However, many patients still experience relapse. This study reveals the presence of pre-leukemic CD34(+)CD19(-)CD22(+) cells, which may contribute to phenotypic escape after CD19-directed immunotherapies.
Article
Cell Biology
Lefu Huang, Jingjing Li, Junfang Yang, Xian Zhang, Min Zhang, Jiujiang He, Gailing Zhang, Wenqian Li, Hui Wang, Jianqiang Li, Peihua Lu
Summary: This study explores the simultaneous targeting of multiple B-cell antigens as a potential treatment for refractory/relapsed B-cell lymphoma. The CAR19/22 T-cell cocktail therapy is found to be effective and safe, with better efficacy in patients treated with a humanized CAR-T therapy compared to a murinized CAR-T therapy.
Article
Medicine, Research & Experimental
Erin M. Wilfong, Katherine N. Vowell, Kaitlyn E. Bunn, Elise Rizzi, Narender Annapureddy, Rosemarie B. Dudenhofer, April Barnado, Rachel H. Bonami, Joyce E. Johnson, Leslie J. Crofford, Peggy L. Kendall
Summary: This study found that CD21(lo/neg) cells are significantly increased in systemic sclerosis patients with interstitial lung disease, indicating a potential biomarker for this condition.
CLINICAL AND EXPERIMENTAL MEDICINE
(2022)
Article
Immunology
Bomiao Ju, Jing Wang, Lingfei Mo, Jing Huang, Zhiming Hao, Xiaohong Lv, Dan Pu, Lan He
Summary: This study found that the proportion of CD19+ Siglec-10+ B cells was significantly elevated in SLE patients and positively correlated with disease activity, while negatively correlated with complement component 3 level. In vitro assays also demonstrated that sera from active SLE patients could increase the proportion of CD19+ Siglec-10+ B cells, while HCQ treatment could decrease their proportions.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Samanta Romina Zanetti, Talia Velasco-Hernandez, Francisco Gutierrez-Aguera, Victor M. Diaz, Paola Alejandra Romecin, Heleia Roca-Ho, Diego Sanchez-Martinez, Nestor Tirado, Matteo Libero Baroni, Paolo Petazzi, Raul Torres-Ruiz, Oscar Molina, Alex Bataller, Jose Luis Fuster, Paola Ballerini, Manel Juan, Irmela Jeremias, Clara Bueno, Pablo Menendez
Summary: CD19-directed CAR T cells have achieved impressive response rates in B-ALL, but relapse remains a challenge. A tandem CAR targeting both CD19 and CD22 showed similar efficacy as CD19-CAR in vitro and in vivo. It is worth exploring whether this approach can enhance leukemia eradication and reduce relapse rates.
Article
Immunology
Jiachen Wang, Kefeng Shen, Wei Mu, Weigang Li, Meilan Zhang, Wei Zhang, Zhe Li, Tong Ge, Zhoujie Zhu, Shangkun Zhang, Caixia Chen, Shugang Xing, Li Zhu, Liting Chen, Na Wang, Liang Huang, Dengju Li, Min Xiao, Jianfeng Zhou
Summary: This study retrospectively evaluated the treatment outcomes of murine CD19/CD22 cocktail CAR T-cell therapy in 135 DLBCL patients. The study found that higher levels of lactate dehydrogenase before leukapheresis and lower cytokine release syndrome grade after CAR T-cell infusion were independent risk factors for T-cell dysfunction. Additionally, a variety of germline variants in genes related to T-cell immunity were significantly enriched in the group with T-cell defects.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Wenjie Li, Lixia Ding, Wenhua Shi, Xinyu Wan, Xiaomin Yang, Jing Yang, Tianyi Wang, Lili Song, Xiang Wang, Yani Ma, Chengjuan Luo, Jingyan Tang, Longjun Gu, Jing Chen, Jun Lu, Yanjing Tang, Benshang Li
Summary: Co-administration of CD19- and CD22-targeted CAR-T cells is a safe and effective therapy for relapsed B-ALL patients, providing an opportunity for long-term survival and bridging to transplantation.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Immunology
Claire F. Beesley, Nina R. Goldman, Taher E. Taher, Christopher P. Denton, David J. Abraham, Rizgar A. Mageed, Voon H. Ong
Summary: Systemic sclerosis (SSc) is an immune-mediated rheumatic disease characterized by excessive extracellular matrix deposition. B cells play a fundamental role in the pathogenesis and development of SSc, as they infiltrate lesional sites and produce profibrotic cytokines. B cell counts are increased in SSc patients and show differences in various B cell compartments. B cell signaling is impaired in SSc patients, and B cell depletion therapy has shown therapeutic benefits.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Dina Schneider, Ying Xiong, Darong Wu, Peirong Hu, Leah Alabanza, Brittany Steimle, Hasan Mahmud, Kim Anthony-Gonda, Winfried Krueger, Zhongyu Zhu, Dimiter S. Dimitrov, Rimas J. Orentas, Boro Dropulic
Summary: Researchers have developed a trispecific duoCAR-T cell strategy to effectively target B cell malignancies with different antigens, showing superior efficacy compared to traditional monoCAR-T cells. The combination of intracellular signaling motifs plays a crucial role in the antitumor effects of duoCAR-T cells.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Review
Immunology
Jing Zheng, Yao Xiao, Xue Q. Wu, Qiong Z. Xiao, Chun Feng, Kai B. Gao
Summary: A case report of a 33-year-old male with secondary CNSL who developed double CRS after CAR T-cell infusion was presented. The patient's symptoms were completely relieved after receiving appropriate treatment strategies, and achieved complete remission.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Yongxian Hu, Yali Zhou, Mingming Zhang, Wengang Ge, Yi Li, Li Yang, Guoqing Wei, Lu Han, Hao Wang, Shuhui Yu, Yi Chen, Yanbin Wang, Xiaohong He, Xingwang Zhang, Ming Gao, Jingjing Yang, Xiuju Li, Jiangtao Ren, He Huang
Summary: The study successfully developed CRISPR-edited universal CAR-T cells as a novel therapy for r/r ALL. Results showed that this therapy has a manageable safety profile and prominent antileukemia activity, providing an alternative treatment option for patients.
CLINICAL CANCER RESEARCH
(2021)
Editorial Material
Rheumatology
Konstantinos Ntelis, Konstantinos Melissaropoulos, Panagiotis Georgiou
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
(2020)
Editorial Material
Rheumatology
Dimitrios Daoussis, Pantelis Kraniotis, Stamatis-Nick Liossis
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
(2021)
Review
Pharmacology & Pharmacy
Stergios Soulaidopoulos, Anastasia-Vasiliki Madenidou, Dimitrios Daoussis, Konstantinos Melissaropoulos, Sophie Mavrogeni, George Kitas, Theodoros Dimitroulas
CURRENT VASCULAR PHARMACOLOGY
(2020)
Review
Pharmacology & Pharmacy
Konstantinos Melissaropoulos, Dimitrios Bogdanos, Theodoros Dimitroulas, Lazaros Sakkas, George D. Kitas, Dimitrios Daoussis
CURRENT VASCULAR PHARMACOLOGY
(2020)
Review
Biochemistry & Molecular Biology
Konstantinos Melissaropoulos, Kalliopi Klavdianou, Alexandra Filippopoulou, Fotini Kalofonou, Haralabos Kalofonos, Dimitrios Daoussis
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Immunology
Zinovia-Maria Kefalopoulou, Stamatis-Nick Liossis, Theodora Sagona, Dimitra Veltsista, Petros Zampakis, Pantelis Kraniotis, Aikaterini Solomou, John Ellul, Elisabeth Chroni
JOURNAL OF NEUROIMMUNOLOGY
(2020)
Editorial Material
Rheumatology
Dimitrios Daoussis, Pantelis Kraniotis, Asimina-Maria Tsimeka, Menelaos Kanakis, Stamatis-Nick Liossis
Review
Rheumatology
Christina Salamaliki, Elena E. Solomou, Stamatis-Nick C. Liossis
RHEUMATOLOGY AND THERAPY
(2020)
Article
Rheumatology
Konstantinos Thomas, Argyro Lazarini, Evripidis Kaltsonoudis, Paraskevi V. Voulgari, Alexandros A. Drosos, Argyro Repa, Ainour Molla Ismail Sali, Prodromos Sidiropoulos, Panagiota Tsatsani, Sousana Gazi, Argyriou Evangelia, Kyriaki A. Boki, Pelagia Katsimbri, Dimitrios Boumpas, Kalliopi Fragkiadaki, Maria G. Tektonidou, Petros P. Sfikakis, Konstantina Karagianni, Lazaros Sakkas, Eleftheria P. Grika, Panagiotis G. Vlachoyiannopoulos, Gerasimos Evangelatos, Alexios Iliopoulos, Theodoros Dimitroulas, Alexandros Garyfallos, Konstantinos Melissaropoulos, Panagiotis Georgiou, Maria Areti, Constantinos Georganas, Periklis Vounotrypidis, Georgios Georgiopoulos, George D. Kitas, Dimitrios Vassilopoulos
Summary: In patients with rheumatoid arthritis, longer disease duration, history of previous serious infections, comorbidities, and high glucocorticoid dose are independently associated with serious infections. The RA Observation of Biologic Therapy (RABBIT) risk score accurately predicted the incidence of serious infections in this study cohort.
Review
Medicine, General & Internal
Stamatis Nick Liossis, Chrysanthi Staveri
Summary: Systemic lupus erythematosus is a chronic autoimmune disease with diverse manifestations, prompting the need for novel treatment options. Recent data highlights ongoing research on severe lupus manifestations, indicating a variety of therapeutic options under investigation despite occasional trial failures.
FRONTIERS IN MEDICINE
(2021)
Review
Rheumatology
Konstantinos Melissaropoulos, Dimitrios Daoussis
Summary: Systemic sclerosis is a debilitating autoimmune disease with unknown pathogenesis, characterized by vascular and immunologic aberrations. B cells play a dysregulated role in the disease, with abnormal subsets observed in peripheral blood and target organs like the skin and lungs. Therapeutic targeting of B cells has shown promise as a treatment alongside current options like mycophenolate.
CLINICAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Charalampos Papagoras, George E. Fragoulis, Nikoleta Zioga, Theodora Simopoulou, Kleopatra Deftereou, Eleni Kalavri, Evangelia Zampeli, Nafsika Gerolymatou, Evangelia Kataxaki, Konstantinos Melissaropoulos, Stylianos Panopoulos, Kalliopi Fragiadaki, Gerasimos Evangelatos, Vasiliki-Kalliopi Bournia, Aikaterini Arida, Anastasios Karamanakos, Maria Pappa, Alexandros Panagiotopoulos, Christos Koutsianas, Georgia Mparouta, Theodoros Dimitroulas, Stamatis-Nick Liossis, Maria G. Tektonidou, Evrydiki Kravvariti, Nikolaos Kougkas, Panagiotis Georgiou, Paraskevi Voulgari, Antonia Elezoglou, Dimitrios P. Bogdanos, Dimitrios Vassilopoulos, Petros P. Sfikakis
Summary: Vaccinated patients with systemic rheumatic diseases who experience breakthrough COVID-19 have better outcomes compared to unvaccinated patients with similar disease characteristics. This highlights the importance of COVID-19 vaccination in vulnerable populations like those with SRDs.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Immunology
Constantina A. Bounia, Stamatis-Nick C. Liossis
Summary: Treatment with rituximab (RTX) significantly reduces circulating Th17 cell percentages in patients with RA, while Tregs remain stable. Reduction of Th17 cells is particularly evident in responders to RTX treatment, ACPA+ and RF (-) patients with RA.
CLINICAL IMMUNOLOGY
(2021)
Review
Medicine, Research & Experimental
Constantina A. Bounia, Eftichia N. Theodoropoulou, Stamatic-Nick C. Liossis
Summary: Renal failure can be a clinical manifestation of rheumatic diseases, and treatment with DMARDs or biologic drugs may lead to nephrotoxicity. Anti-TNF-alpha treatment in patients with SpA may induce renal failure, particularly in cases of IgA nephropathy. It is important to be cautious when using anti-TNF-alpha agents in patients with rheumatic diseases presenting with renal manifestations.
BIOLOGICS-TARGETS & THERAPY
(2021)
Article
Rheumatology
Konstantinos Thomas, Argiro Lazarini, Evripidis Kaltsonoudis, Alexandros Drosos, Ioannis Papalopoulos, Prodromos Sidiropoulos, Panagiota Tsatsani, Sousana Gazi, Lina Pantazi, Kyriaki A. Boki, Pelagia Katsimbri, Dimitrios Boumpas, Kalliopi Fragkiadaki, Maria Tektonidou, Petros P. Sfikakis, Konstantina Karagianni, Lazaros I. Sakkas, Eleftheria P. Grika, Panagiotis G. Vlachoyiannopoulos, Gerasimos Evangelatos, Alexios Iliopoulos, Theodoros Dimitroulas, Alexandros Garyfallos, Konstantinos Melissaropoulos, Panagiotis Georgiou, Maria Areti, Constantinos Georganas, Periklis Vounotrypidis, George D. Kitas, Dimitrios Vassilopoulos
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2020)